激进投资者卡尔·伊坎 (Carl Icahn) 放弃了针对 Illumina 的第二次代理权争夺，原因是该公司计划在监管机构的反对下出售 Grail。 Activist investor Carl Icahn abandons second proxy contest against Illumina due to company's plan to sell Grail amid regulatory opposition.
据报道，激进投资者卡尔·伊坎 (Carl Icahn) 放弃了第二次代理权争夺的计划，即 DNA 测序公司 Illumina 计划在监管机构的强烈反对下出售 Grail，以清除更多董事会成员。 Activist investor Carl Icahn has reportedly abandoned his plan for a second proxy contest to remove more board members from Illumina, a DNA sequencing company, due to the company's plan to sell Grail amid significant regulatory opposition. 消息传出后，Illumina 股价下跌 4%。 Illumina's shares fell by 4% following the news. 伊坎仍打算坚持去年对 Illumina 董事提起的诉讼，指控他们收购 Grail 违反了信托义务，尽管监管机构存在反垄断担忧。 Icahn still intends to persist with the lawsuit he filed against Illumina directors last year, alleging they broke their fiduciary duties by acquiring Grail despite antitrust concerns from regulators.